Abstract
The recent technological achievements in biotechnology and recombinant DNA technology have provided multiple new methods, molecular targets, and DNA-based diagnostics to pharmaceutical research that can be utilized in assays for screening and developing potential biotechnology-based drugs, as well as in biomedicine, health and pharmaceutical care. Furthermore, such advances opened up new opportunities by applying genetic information data in pharmacotherapy and drug delivery, thus ensuring better drug efficacy and safety in clinical practice. Now the concepts of personalized medicine and pharmacogenomics are likely improving the area of pharmacodynamics and pharmacokinetics, since they favor differentiation of the conventional clinical diagnosis and drug selection into separate molecular subtypes of individuals belonging within a group of patients suffering from the same disease. Genetic polymorphisms have already been detected and analyzed in genes encoding drug-metabolizing enzymes, transporters as well as targets (e.g. receptors). The potential of applying genotyping and haplotyping analysis in future pharmaceutical care could eventually lead to pharmacotyping, i.e. individualized drug delivery profiling based on genetic-bioinformatic data in routine patient care. However, the steps towards this direction of drug delivery in clinical practice still have a long way to go to be fully achieved; until then, the critical evaluation of all available clinical data including pharmacodynamic, pharmacokinetic and genomic must be assessed for ensuring drug efficacy and safety. In this way, there has been great progress in elucidating genetic determinants contributing to the observed interindividual differences in drug disposition and effects, thus implementing current drug delivery with molecular genetics and diagnostics.
Keywords: pharmacogenomics, drug delivery, personalized medicine, pharmacotyping, gene polymorphisms, snps, haplotyping, genotyping, drug prescribing
Current Drug Delivery
Title: Challenges in Current Drug Delivery from the Potential Application of Pharmacogenomics and Personalized Medicine in Clinical Practice
Volume: 1 Issue: 1
Author(s): Ioannis S. Vizirianakis
Affiliation:
Keywords: pharmacogenomics, drug delivery, personalized medicine, pharmacotyping, gene polymorphisms, snps, haplotyping, genotyping, drug prescribing
Abstract: The recent technological achievements in biotechnology and recombinant DNA technology have provided multiple new methods, molecular targets, and DNA-based diagnostics to pharmaceutical research that can be utilized in assays for screening and developing potential biotechnology-based drugs, as well as in biomedicine, health and pharmaceutical care. Furthermore, such advances opened up new opportunities by applying genetic information data in pharmacotherapy and drug delivery, thus ensuring better drug efficacy and safety in clinical practice. Now the concepts of personalized medicine and pharmacogenomics are likely improving the area of pharmacodynamics and pharmacokinetics, since they favor differentiation of the conventional clinical diagnosis and drug selection into separate molecular subtypes of individuals belonging within a group of patients suffering from the same disease. Genetic polymorphisms have already been detected and analyzed in genes encoding drug-metabolizing enzymes, transporters as well as targets (e.g. receptors). The potential of applying genotyping and haplotyping analysis in future pharmaceutical care could eventually lead to pharmacotyping, i.e. individualized drug delivery profiling based on genetic-bioinformatic data in routine patient care. However, the steps towards this direction of drug delivery in clinical practice still have a long way to go to be fully achieved; until then, the critical evaluation of all available clinical data including pharmacodynamic, pharmacokinetic and genomic must be assessed for ensuring drug efficacy and safety. In this way, there has been great progress in elucidating genetic determinants contributing to the observed interindividual differences in drug disposition and effects, thus implementing current drug delivery with molecular genetics and diagnostics.
Export Options
About this article
Cite this article as:
Vizirianakis S. Ioannis, Challenges in Current Drug Delivery from the Potential Application of Pharmacogenomics and Personalized Medicine in Clinical Practice, Current Drug Delivery 2004; 1 (1) . https://dx.doi.org/10.2174/1567201043480009
DOI https://dx.doi.org/10.2174/1567201043480009 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advancements in Robotic and AI-Based Drug Discovery and Delivery for Neurological Disorders
Neurological disorders, including Alzheimer's disease, Parkinson's disease, epilepsy, and brain tumors, pose significant challenges in drug delivery due to the blood-brain barrier's intricate structure and the complexity of neuronal networks. Traditional drug delivery methods often fall short in reaching therapeutic concentrations within the central nervous system, limiting treatment efficacy and ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access to both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Extracellular Vesicles as Drug Delivery Systems.
Extracellular vesicles (EVs) are membranous vesicles released from almost all types of cells into extracellular space. EVs are categorized into different types including exosome (~30-150 nm), microvesicle or microparticle (~100-1,000 nm), apoptotic body (~1,000-5,000 nm), and others produced by different mechanisms. Since EVs bear the molecules (e.g., specific lipids, carbohydrates, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review on Solvent-free Methods in Organic Synthesis
Current Organic Chemistry Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry Surfactant Protein (SP)-A and SP-D as Antimicrobial and Immunotherapeutic Agents
Recent Patents on Anti-Infective Drug Discovery Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology Overview of the Primary Structure, Tissue-Distribution, and Functions of Tachykinins and their Receptors
Current Drug Targets Application of In Vivo Animal Models to Characterize the Pharmacokinetic and Pharmacodynamic Properties of Drug Candidates in Discovery Settings
Combinatorial Chemistry & High Throughput Screening Saccharomyces cerevisiae as a Model for Screening the Effects of Volatile Organic Compounds
Current Biotechnology Combination Therapy with Favipiravir for Treatment of Hospitalized COVID-19 Adults
New Emirates Medical Journal Subject Index
Current Drug Targets - Inflammation & Allergy Measurement of Antioxidant Activity and Antioxidant Compounds under Versatile Extraction Conditions: I. The Immuno-Biochemical Antioxidant Properties of Sweet Cherry (Prunus avium) Extracts
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prevalence and Factors Associated With Low Aerobic Performance Levels in Adolescents: A Systematic Review
Current Pediatric Reviews Relationship Between Atopic Dermatitis and Food Allergy
Current Pediatric Reviews New Ways of Detecting ADRs in Neonates and Children
Current Pharmaceutical Design Editorial (Hot Topic : Computational Prediction of Drug-Target Interactions in Medicinal Chemistry)
Current Topics in Medicinal Chemistry Recent Advances in Drug Repurposing for Parkinson’s Disease
Current Medicinal Chemistry The Use of Carvedilol in Pediatric Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Occupational Respiratory Pathology in Russia: Current Trends and Challenges
Current Respiratory Medicine Reviews PEGylation Strategy for Improving the Pharmacokinetic and Antitumoral Activity of the IL-2 No-alpha Mutein
Current Pharmaceutical Design Respiratory Effects of β-Adrenergic Receptor Blockers
Current Medicinal Chemistry